Current evidence and future research needs for FeNO measurement in respiratory diseases
Leif Bjermer(Lund University), Omar S. Usmani(Imperial College London), David Price(University of Aberdeen), Giorgio Piacentini(University of Verona), Mike Thomas(University of Southampton), Ian Pavord(University of Oxford), Kjell Alving(Uppsala University), J. Sastre(Hospital Universitario Fundación Jiménez Díaz), Nicolás Roche(Centre d'Investigation Clinique - Innovation Technologique), H Magnussen(Apple (Israel)), Zuzana Diamant(Lund University)
Cited by 183
Related Papers
Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients
|Science|2020|3.2k
Withdrawal of Inhaled Glucocorticoids and Exacerbations of COPD
|New England Journal of Medicine|2014|621
Blood eosinophil count and prospective annual asthma disease burden: a UK cohort study
|The Lancet Respiratory Medicine|2015|584
MEDI-563, a humanized anti–IL-5 receptor α mAb with enhanced antibody-dependent cell-mediated cytotoxicity function
|Journal of Allergy and Clinical Immunology|2010|578
An official European Respiratory Society statement on physical activity in COPD
|European Respiratory Journal|2014|519